NA In-Vitro Toxicology Testing Market - Industry Trends and Forecast to 2030
The North America in-vitro toxicology testing market is expected to reach USD 11,902.69 Million by 2030 from USD 4,163.02 Million in 2022, growing at a CAGR of 14.0% during the forecast period of 2023 to 2030.
Market SegmentationNorth America In-Vitro Toxicology Testing Market, By Product and Service (Consumables, Services, Assays, Equipments, and Software), Toxicology End Point and Test (Adme (Absorption, Distribution, Metabolism, & Excretion) Testing, Cytotoxicity Testing, Genotoxicity Testing, Dermal Toxicity Testing, Ocular Toxicity Testing, Organ Toxicity Testing, Skin Irritation, Corrosion, & Sensitization Testing, Phototoxicity Testing, and Other Toxicity Endpoints & Tests), Technology (Cell Culture Technologies, High-Throughput Technologies, Molecular Imaging, and Omics Technology), Method (Cellular Assays, Biochemical Assays, Ex-Vivo Models, and In Silico Models), Industry (Pharmaceutical & Biopharmaceutical Companies, Diagnostics, Food, Chemicals, Cosmetics & Household Products), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (U.S., Canada, and Mexico) - Industry Trends and Forecast to 2030
Overview of North America In-Vitro Toxicology Testing Market Dynamics:Driver
• Rising investment in R&D by key market players
Restrain
• Complexity of biological systems
Opportunity
• Technological advancements to develop new toxicology testing methods
Market PlayersSome of the major market players operating in the North America in-vitro toxicology testing market are:• Thermo Fisher Scientific Inc.
• Labcorp Drug Development
• Merck KGaA
• Charles River Laboratories
• Lonza
• Eurofins Scientific
• SGS Société Générale de Surveillance SA
• Bio-Rad Laboratories, Inc.
• QIAGEN
• Cyprotex Plc.